These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7884791)

  • 1. Long-term efficacy and safety of moexipril in the treatment of hypertension.
    White WB; Fox AA; Stimpel M
    J Hum Hypertens; 1994 Dec; 8(12):917-21. PubMed ID: 7884791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension.
    White WB; Stimpel M
    J Hum Hypertens; 1995 Nov; 9(11):879-84. PubMed ID: 8583466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension.
    White WB; Koch B; Stimpel M
    Am J Ther; 1997 Apr; 4(4):123-9. PubMed ID: 10423601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension.
    Stimpel M; Koch B; Dickstein K
    Cardiology; 1996; 87(4):313-8. PubMed ID: 8793166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.
    Persson B; Stimpel M
    Eur J Clin Pharmacol; 1996; 50(4):259-64. PubMed ID: 8803515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).
    Stimpel M; Koch B; Oparil S
    Cardiology; 1998 May; 89(4):271-6. PubMed ID: 9643274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension.
    Dickstein K; Aarsland T; Ferrari P; Todd M; Stimpel M
    J Cardiovasc Pharmacol; 1994 Aug; 24(2):247-55. PubMed ID: 7526056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
    Chrysant SG; Fox AA; Stimpel M
    Am J Hypertens; 1995 Apr; 8(4 Pt 1):418-21. PubMed ID: 7619356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide.
    Chrysant SG; Stimpel M
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):384-90. PubMed ID: 9514183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause.
    Agabiti-Rosei E; Ambrosioni E; Pirelli A; Stimpel M; Zanchetti A
    Eur J Clin Pharmacol; 1999 May; 55(3):185-9. PubMed ID: 10379633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of the new angiotensin-converting enzyme inhibitor moexipril on the circadian rhythms of arterial pressure in hypertension patients].
    Ol'binskaia LI; Andrushchishina TB
    Ter Arkh; 1997; 69(3):58-61. PubMed ID: 9229835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring.
    White WB; Whelton A; Fox AA; Stimpel M; Kaihlanen PM
    J Clin Pharmacol; 1995 Mar; 35(3):233-8. PubMed ID: 7608310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moexipril versus captopril in patients with mild to moderate hypertension.
    Stimpel M; Koch B; Jansen T; Fox A; Loh I
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):769-73. PubMed ID: 8961074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension.
    Stimpel M; Koch B
    J Hum Hypertens; 1997 Feb; 11(2):133-7. PubMed ID: 9140801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension.
    Persson B; Widgren BR; Fox A; Stimpel M
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):73-8. PubMed ID: 7564369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.